Harry Lander
Vermögen: - $ am 30.09.2026
Vermögen: - $ am 30.09.2026
Harry M.
Lander is currently the Chief Executive Officer at Canary Oncoceutics, Inc., the Director at Federation Employment & Guidance Service, Inc., and the Director at Capo Therapeutics, Inc. Previously, he held the position of President, Director & Chief Scientific Officer at Zander Therapeutics, Inc. from 2018 to 2019, and President & Chief Scientific Officer at Regen Biopharma, Inc. from 2015 to 2019.
He also served as the Head-Administration at Sidra Medical & Research Center.
In addition, he will be the Chief Scientific Officer at SYBLEU, Inc. from 2022 to 2024.
Dr. Lander obtained his undergraduate degree from Stony Brook University.
He also holds an MBA from The Leonard N Stern School of Business, which he received in 1991.
Furthermore, he earned a doctorate degree from Weill Cornell Graduate School of Medical Sciences in 1992.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
REGEN BIOPHARMA, INC. 22.72% | 10.11.2025 | 6’667 ( 22.72% ) | - $ | 30.09.2026 |
| 10.11.2025 | 20’020’001 ( 1.03% ) | - $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
Federation Employment & Guidance Service, Inc.
Federation Employment & Guidance Service, Inc. Services to the Health IndustryHealth Services Provides health and human services | Direktor/Vorstandsmitglied | 16.09.2009 |
Capo Therapeutics, Inc.
Capo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops peptide and epitope vaccines for alzheimer's disease | Direktor/Vorstandsmitglied | - |
Canary Oncoceutics, Inc.
Canary Oncoceutics, Inc. BiotechnologyHealth Technology Develops precision oncology testing platform | Vorstandsvorsitzender | - |
| Unternehmen | Position | Ende |
|---|---|---|
| SYBLEU INC. | Technik-/Wissenschafts-/F&E-Leiter | 12.04.2024 |
| REGEN BIOPHARMA, INC. | Präsident | 22.01.2019 |
Zander Therapeutics, Inc.
Zander Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for cancer | Präsident | 22.01.2019 |
Sidra Medical & Research Center
Sidra Medical & Research Center Miscellaneous Commercial ServicesCommercial Services Operates as a medical research organisation | Verwaltungsdirektor | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Regen Biopharma, Inc.
Regen Biopharma, Inc. BiotechnologyHealth Technology Develops regenerative medicine therapies and tools | Health Technology |
Stony Brook University
Stony Brook University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Federation Employment & Guidance Service, Inc.
Federation Employment & Guidance Service, Inc. Services to the Health IndustryHealth Services Provides health and human services | Health Services |
Sidra Medical & Research Center
Sidra Medical & Research Center Miscellaneous Commercial ServicesCommercial Services Operates as a medical research organisation | Commercial Services |
The Leonard N Stern School of Business
The Leonard N Stern School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Weill Cornell Graduate School of Medical Sciences
Weill Cornell Graduate School of Medical Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zander Therapeutics, Inc.
Zander Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for cancer | Health Technology |
Capo Therapeutics, Inc.
Capo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops peptide and epitope vaccines for alzheimer's disease | Health Technology |
SYBLEU, Inc.
SYBLEU, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as an early-stage company which intends to develop regenerative medical applications | Commercial Services |
Canary Oncoceutics, Inc.
Canary Oncoceutics, Inc. BiotechnologyHealth Technology Develops precision oncology testing platform | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen